Abstract:

Mucormycosis is a fungal infection which get worsens with time if not diagnosed and treated. The present COVID-19 pandemic has been associated with mucormycosis, an infection caused by fungi. Patients who possess impaired immune systems are easy targets for COVID-19 and mucormycosis. As COVID-19 infection results in a weakened immune system, COVID-19 patients have relatively high infection risk. Additionally, as we pointed out in case studies below, diabetes, corticosteroids, and a compromised immune system are the most common risk factors for this infection. Patients with COVID-19 who get steroids can experience adverse impacts on their health, and the condition frequently experiences diseases such mucormycosis.There are therapies, however they are less successful and not as optimistic. Therefore, the focus of study is to investigate potential treatments for mucormycosis. According to reports, mucormycosis has been successfully treated early on using liposomal amphotericin B (AmB), manogepix, echinocandinsisavuconazole, posaconazole, and other promising therapeutic agents. Due to their higher safety and efficacy, lipid formulations of AmB have replaced other treatments for mucormycosis as the norm. We included case reports involving mucormycosis infections in COVID-19 patients in the present study.For component of an immediate worldwide reaction to prevent and treat this deadly disease, particularly for individuals with documented risks, we also focused on anti-mucormycosis drugs including mechanisms of action of different therapeutics, including coverage of new antifungal medications under investigation.

Keywords: